|
End-of-day quote
London S.E.
05/02/2024
|
5-day change | 1st Jan Change | ||
| 0.3500 GBX | -.--% |
|
-.--% | - |
| 28/08 | WINNERS & LOSERS: McBride rises on deal win; Watkin Jones slumps | AN |
| 29/05 | WINNERS & LOSERS: CelLBxHealth jumps on AstraZeneca partnership | AN |
Company Valuation: VERU CAPI
Data adjusted to current consolidation scope
| Fiscal Period: May | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|
| Market Cap 1 | 0.54 | 1.38 | 1.872 | 8.289 | 3.553 |
| Change | - | 155.56% | 35.65% | 342.81% | - |
| Enterprise Value (EV) 1 | 0.3487 | 1.069 | 3.169 | 10.86 | 6.747 |
| Change | - | 206.59% | 196.42% | 242.75% | - |
| P/E | -4.19x | -10.4x | -9.08x | -44.3x | -2.94x |
| PBR | 3.95x | 7.2x | 3.49x | 0.92x | 0.39x |
| PEG | - | -3.19x | -0.3x | 0.5x | - |
| Capitalization / Revenue | - | - | 1,35,364x | 14,87,450x | 3,20,103x |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | -2.71x | -7.3x | 47.1x | -189x | -8.03x |
| EV / FCF | -6.2x | -16.4x | -18.5x | -10.9x | - |
| FCF Yield | -16.1% | -6.12% | -5.4% | -9.17% | - |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -0.001073 | -0.001108 | -0.001432 | -0.000079 | -0.000511 |
| Distribution rate | - | - | - | - | - |
| Net sales | - | - | 13.83 | 5.573 | 11.1 |
| EBITDA | - | - | 0.091 | -0.0403 | -0.8263 |
| EBIT 1 | -0.1288 | -0.1465 | 0.0673 | -0.0575 | -0.8404 |
| Net income 1 | -0.1288 | -0.1465 | -3.146 | -0.1875 | -1.215 |
| Net Debt 1 | -0.1913 | -0.311 | 1.297 | 2.571 | 3.195 |
| Reference price 2 | 0.004500 | 0.011500 | 0.013000 | 0.003500 | 0.001500 |
| Nbr of stocks (in thousands) | 1,20,000 | 1,20,000 | 1,44,000 | 23,68,395 | 23,68,395 |
| Announcement Date | 30/06/21 | 31/05/22 | 30/04/24 | 30/04/24 | 14/10/25 |
1GBP in Million2GBP
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 11.99x | 1.25x | 5.37x | 2.42% | 1.71TCr | ||
| 7.72x | 14.82x | - | -.--% | 1.47TCr | ||
| 6.21x | 9.63x | 28.1x | 2.55% | 1.2TCr | ||
| Average | 8.64x | 8.57x | 16.74x | 1.66% | 1.46TCr | |
| Weighted average by Cap. | 8.98x | 8.10x | 14.71x | 1.64% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- VOX Stock
- VCBC Stock
- Valuation VERU CAPI
Select your edition
All financial news and data tailored to specific country editions
















